FDAsafety guidance72% confidence
Guidance Documents for Rare Disease Drug Development
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (ophthalmology) as Viridian Therapeutics.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Ophthalmology · Thyroid Eye Disease
- Sub-indication
- Ophthalmology
Related signal: Viridian Therapeutics initiates trial for VRDN-003 in Thyroid Eye Disease